Published in Nat Med on February 01, 1997
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest (1999) 2.86
Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation (2011) 1.74
Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.71
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol (2001) 1.54
Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest (2003) 1.52
Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A (1999) 1.23
Therapeutic angiogenesis. BMJ (1999) 1.15
Stimulus-dependent phosphorylation of profilin-1 in angiogenesis. Nat Cell Biol (2012) 1.12
Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci U S A (2007) 1.09
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf (2012) 1.08
Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc (2013) 1.05
Tissue engineered scaffolds in regenerative medicine. World J Plast Surg (2014) 0.99
Human recombinant vascular endothelial growth factor reduces necrosis and enhances hepatocyte regeneration in a mouse model of acetaminophen toxicity. J Pharmacol Exp Ther (2010) 0.92
Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. Br J Pharmacol (2001) 0.86
Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 1: Cardiovascular progenitor cells, their functions and sources. Neth Heart J (2008) 0.86
Hyaluronic acid-human blood hydrogels for stem cell transplantation. Biomaterials (2012) 0.85
Angiogenesis and the heart: therapeutic implications. J R Soc Med (1997) 0.84
Novel revascularization therapies--TMLR and growth factor-induced angiogenesis monitored with cardiac MRI. MAGMA (2000) 0.81
ARHGAP18: an endogenous inhibitor of angiogenesis, limiting tip formation and stabilizing junctions. Small GTPases (2014) 0.81
Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. Heart Fail Rev (2007) 0.80
Vascular endothelial growth factor in children with cyanotic and acyanotic and congenital heart disease. Arch Med Sci (2010) 0.79
Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction. Mol Med Rep (2015) 0.79
Increased cardiac distribution of mono-PEGylated Radix Ophiopogonis polysaccharide in both myocardial infarction and ischemia/reperfusion rats. Int J Nanomedicine (2015) 0.77
Simultaneous in vivo imaging of blood and lymphatic vessel growth in Prox1-GFP/Flk1::myr-mCherry mice. FEBS J (2015) 0.77
Therapeutic Angiogenesis for Coronary Artery Disease. Curr Treat Options Cardiovasc Med (2002) 0.76
Imaging of angiogenesis in cardiology. Eur J Nucl Med Mol Imaging (2007) 0.76
Targeting delivery of Radix Ophiopogonis polysaccharide to ischemic/reperfused rat myocardium by long-circulating macromolecular and liposomal carriers. Int J Nanomedicine (2015) 0.75
Human adipose-derived mesenchymal stem cell spheroids improve recovery in a mouse model of elastase-induced emphysema. BMB Rep (2016) 0.75
Hyaluronic acid-serum hydrogels rapidly restore metabolism of encapsulated stem cells and promote engraftment. Biomaterials (2015) 0.75
The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties. Saudi Pharm J (2011) 0.75
Mosaic organization of DNA nucleotides. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1994) 10.43
Long-range correlations in nucleotide sequences. Nature (1992) 8.93
Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 3.50
Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest (2001) 3.22
Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med (1995) 2.29
Evidence implicating nonmuscle myosin in restenosis. Use of in situ hybridization to analyze human vascular lesions obtained by directional atherectomy. Circulation (1992) 2.20
Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res (2000) 2.06
Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation (2000) 2.05
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature (1990) 1.87
Synectin, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J Cell Physiol (2000) 1.82
Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium). Eur J Nucl Med (1998) 1.79
Long-range correlation properties of coding and noncoding DNA sequences: GenBank analysis. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1995) 1.78
VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol (1996) 1.75
Linguistic features of noncoding DNA sequences. Phys Rev Lett (1994) 1.75
Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation (1997) 1.72
Tomato seed and root exudate sugars: composition, utilization by Pseudomonas biocontrol strains and role in rhizosphere colonization. Environ Microbiol (1999) 1.67
Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem (2000) 1.58
Fractal landscapes in biological systems: long-range correlations in DNA and interbeat heart intervals. Physica A (1992) 1.48
Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res (1999) 1.45
A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma. Eur J Nucl Med (1993) 1.44
An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol (2001) 1.43
Pericardial effusion in patients with cancer: outcome with contemporary management strategies. Heart (1996) 1.43
Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J (1985) 1.35
Generalized Lévy-walk model for DNA nucleotide sequences. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1993) 1.35
Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun (1999) 1.28
Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest (2000) 1.27
Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res (2001) 1.26
The beta-amyloid domain is essential for axonal sorting of amyloid precursor protein. EMBO J (1996) 1.26
Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc Natl Acad Sci U S A (1997) 1.26
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J (2001) 1.20
Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Calpha. J Biol Chem (1998) 1.18
Scaling features of noncoding DNA. Physica A (1999) 1.18
Finite-size effects on long-range correlations: implications for analyzing DNA sequences. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1993) 1.17
Statistical properties of DNA sequences. Physica A (1995) 1.16
Macrophage-dependent regulation of syndecan gene expression. Circ Res (1997) 1.15
Systematic analysis of coding and noncoding DNA sequences using methods of statistical linguistics. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1995) 1.15
beta-Adrenergic receptors contribute to hypoxaemia induced vasodilation in man. Br J Clin Pharmacol (1995) 1.14
Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation (1999) 1.13
The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J Biol Chem (1999) 1.13
Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg (1998) 1.11
Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol (1996) 1.11
Re-evaluating therapeutic neovascularization. J Mol Cell Cardiol (2004) 1.09
Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest (1994) 1.09
Progress and prospects: gene therapy clinical trials (part 1). Gene Ther (2007) 1.09
Enhancement of migration by protein kinase Calpha and inhibition of proliferation and cell cycle progression by protein kinase Cdelta in capillary endothelial cells. J Biol Chem (1997) 1.08
Stretch-induced VEGF expression in the heart. J Clin Invest (1997) 1.08
Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation (1998) 1.07
Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol (2000) 1.06
Fractal landscapes and molecular evolution: modeling the myosin heavy chain gene family. Biophys J (1993) 1.06
Air travel and adults with cyanotic congenital heart disease. Circulation (1996) 1.06
Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol (1996) 1.05
Phosphatidylinositol-4,5-bisphosphate mediates the interaction of syndecan-4 with protein kinase C. Biochemistry (1999) 1.05
Lipomatous hypertrophy of the atrial septum: diagnosis by combined echocardiography and computerized tomography. Am J Cardiol (1984) 1.05
Receiver-operating-characteristic study of chest radiographs in children: digital hard-copy film vs 2K x 2K soft-copy images. AJR Am J Roentgenol (1992) 1.05
Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos (1999) 1.04
Statistical mechanics in biology: how ubiquitous are long-range correlations? Physica A (1994) 1.03
Myocyte-dependent regulation of endothelial cell syndecan-4 expression. Role of TNF-alpha. J Biol Chem (1999) 1.03
Serotonin-induced coronary contraction increases after blood cardioplegia-reperfusion: role of COX-2 expression. Circulation (1999) 1.02
Non-equilibrium dynamics as an indispensable characteristic of a healthy biological system. Integr Physiol Behav Sci (1995) 1.01
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation (2000) 1.00
Correlation approach to identify coding regions in DNA sequences. Biophys J (1994) 1.00
PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol (2001) 1.00
Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery (1996) 1.00
Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther (2000) 1.00
VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res (1998) 0.99
Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J Thorac Cardiovasc Surg (1998) 0.98
Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol (2001) 0.97
Fractals in biology and medicine. Chaos Solitons Fractals (1995) 0.96
Regulation of syndecan-4 phosphorylation in vivo. J Biol Chem (1998) 0.95
Fractal landscape analysis of DNA walks. Physica A (1992) 0.94
Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. Eur J Nucl Med (1998) 0.93
Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med (2001) 0.92
Regulation of vascular smooth muscle cell proliferation by plasma membrane Ca(2+)-ATPase. Am J Physiol (1997) 0.92
Effects of ischemic preconditioning on myocardial perfusion, function, and microvascular regulation. Circulation (1998) 0.91
Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol (1998) 0.91
Salvage of the carotid artery with covered stent after perforation with dialysis sheath. A case report. Interv Neuroradiol (2012) 0.91
FZD6 encoding the Wnt receptor frizzled 6 is mutated in autosomal-recessive nail dysplasia. Br J Dermatol (2012) 0.91
Measurement of gastric blood flow with radioactive microspheres. J Appl Physiol (1975) 0.89
Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol (1997) 0.89
Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol (2001) 0.89
Angiographic methods to assess human coronary angiogenesis. Am Heart J (1999) 0.89
Uptake of 13N-ammonia by human tumours as studied by positron emission tomography. Br J Radiol (1982) 0.88
Postburn serum drug binding and serum protein concentrations. J Clin Pharmacol (1986) 0.86
Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J Biol Chem (1998) 0.86
Subxyphoid access of the normal pericardium: a novel drug delivery technique. Catheter Cardiovasc Interv (1999) 0.85
Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg (2000) 0.85
Multiple hepatic abscesses: cholangiographic changes simulating sclerosing cholangitis and resolution after percutaneous drainage. Am J Gastroenterol (1990) 0.84
Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. Am J Physiol Heart Circ Physiol (2000) 0.83
Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation. Am J Physiol (1994) 0.83
Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol (1998) 0.83
Rat arterial wall retains myointimal hyperplastic potential long after arterial injury. Circulation (1997) 0.83
c-Myb-dependent cell cycle progression and Ca2+ storage in cultured vascular smooth muscle cells. Circ Res (1997) 0.83
Comparison of transendocardial and retrograde coronary venous intramyocardial catheter delivery systems in healthy and infarcted pigs. Catheter Cardiovasc Interv (2006) 0.83
Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thorac Cardiovasc Surg (2001) 0.83
The rational phase of therapeutic angiogenesis. Minerva Cardioangiol (2003) 0.82
Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation--preliminary study in pigs. Radiology (2000) 0.82
Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation. J Thorac Cardiovasc Surg (1998) 0.82
Improvement in oxygenation after large volume paracentesis. South Med J (1996) 0.82